J&J, Abbott Labs and Allergan Among Wells Fargo’s Heaviest Healthcare Stock Holdings

Wall St. Watchdog reveals information regarding Wells Fargo Co.’s top holdings in the Healthcare sector for the quarter ending September 30th, 2011. The firm held 427 stocks in the Healthcare sector at the end of the quarter with an aggregate market value of $9.358 billion.

  • Johnson & Johnson (NYSE:JNJ): On 06/30/2011, Wells Fargo Co. reported holding 13,186,212 shares with a market value of $877,146,778. This comprised 0.6% of the total portfolio. On 09/30/2011, Wells Fargo Co. reported holding 13,107,652 shares with a market value of $834,826,338. This comprised 0.69% of the total portfolio. The net change in shares for this position over the two quarters is -78,560. About Company: Johnson & Johnson manufactures health care products and provides related services for the consumer, pharmaceutical, and medical devices and diagnostics markets. The Company sells products such as skin and hair care products, acetaminophen products, pharmaceuticals, diagnostic equipment, and surgical equipment in countries located around the world.
  • Abbott Laboratories (NYSE:ABT): On 06/30/2011, Wells Fargo Co. reported holding 12,194,360 shares with a market value of $641,667,210. This comprised 0.44% of the total portfolio. On 09/30/2011, Wells Fargo Co. reported holding 11,816,896 shares with a market value of $604,316,054. This comprised 0.5% of the total portfolio. The net change in shares for this position over the two quarters is -377,464. About Company: Abbott Laboratories discovers, develops, manufactures, and sells a broad and diversified line of health care products and services. The Company’s products include pharmaceuticals, nutritional, diagnostics, and vascular products. Abbott markets its products worldwide through affiliates and distributors.
  • Allergan Inc. (NYSE:AGN): On 06/30/2011, Wells Fargo Co. reported holding 5,411,556 shares with a market value of $450,512,037. This comprised 0.31% of the total portfolio. On 09/30/2011, Wells Fargo Co. reported holding 6,784,858 shares with a market value of $558,936,583. This comprised 0.46% of the total portfolio. The net change in shares for this position over the two quarters is 1,373,302. About Company: Allergan, Inc. is a multi-specialty health care company that discovers, develops and commercializes pharmaceuticals, biologics and medical devices. The Company develops products for the ophthalmic, neurological, medical aesthetics, medical dermatology, breast aesthetics, obesity intervention, urological and other specialty markets in countries around the world.
  • Unitedhealth Group Inc. (NYSE:UNH): On 06/30/2011, Wells Fargo Co. reported holding 10,619,908 shares with a market value of $547,774,874. This comprised 0.38% of the total portfolio. On 09/30/2011, Wells Fargo Co. reported holding 10,832,982 shares with a market value of $499,617,118. This comprised 0.41% of the total portfolio. The net change in shares for this position over the two quarters is 213,074. About Company: UnitedHealth Group Incorporated owns and manages organized health systems in the United States and internationally. The Company provides employers products and resources to plan and administer employee benefit programs. UnitedHealth also serves the health needs of older Americans, provides specialized care services, and provides health care information and research to providers and payers.
  • Alexion Pharmaceuticals Inc. (NASDAQ:ALXN): On 06/30/2011, Wells Fargo Co. reported holding 5,555,280 shares with a market value of $261,264,812. This comprised 0.18% of the total portfolio. On 09/30/2011, Wells Fargo Co. reported holding 6,928,991 shares with a market value of $443,871,147. This comprised 0.36% of the total portfolio. The net change in shares for this position over the two quarters is 1,373,711. About Company: Alexion Pharmaceuticals, Inc., a biopharmaceutical company, researches and develops proprietary immunoregulatory compounds for the treatment of autoimmune and cardiovascular diseases. The Company develops C5 complement inhibitors and Apogens which are two classes of potential therapeutic compounds designed to selectively target specific disease-causing segments of the immune system.
  • Eli Lilly & Co. (NYSE:LLY): On 06/30/2011, Wells Fargo Co. reported holding 9,303,387 shares with a market value of $349,156,103. This comprised 0.24% of the total portfolio. On 09/30/2011, Wells Fargo Co. reported holding 8,887,752 shares with a market value of $328,580,202. This comprised 0.27% of the total portfolio. The net change in shares for this position over the two quarters is -415,635. About Company: Eli Lilly and Company discovers, develops, manufactures, and sells pharmaceutical products for humans and animals. The Company’s products are sold in countries around the world. Eli Lilly’s products include neuroscience products, endocrine products, anti-infectives, cardiovascular agents, oncology products, and animal health products.
  • Pfizer Inc. (NYSE:PFE): On 06/30/2011, Wells Fargo Co. reported holding 19,784,155 shares with a market value of $407,553,601. This comprised 0.28% of the total portfolio. On 09/30/2011, Wells Fargo Co. reported holding 17,043,970 shares with a market value of $301,337,395. This comprised 0.25% of the total portfolio. The net change in shares for this position over the two quarters is -2,740,185. About Company: Pfizer Inc. is a research-based, global pharmaceutical company that discovers, develops, manufactures, and markets medicines for humans and animals. The Company’s products include prescription pharmaceuticals, non-prescription self-medications, and animal health products such as anti-infective medicines and vaccines.
  • Bristol-myers Squibb Company (NYSE:BMY): On 06/30/2011, Wells Fargo Co. reported holding 7,864,232 shares with a market value of $227,748,152. This comprised 0.16% of the total portfolio. On 09/30/2011, Wells Fargo Co. reported holding 9,166,186 shares with a market value of $287,634,909. This comprised 0.24% of the total portfolio. The net change in shares for this position over the two quarters is 1,301,954. About Company: Bristol-Myers Squibb Company is a global biopharmaceutical company that discovers, develops, manufactures and sells pharmaceutical and nutritional products. The Company’s products and experimental therapies address cancer, heart disease, HIV/AIDS, diabetes, rheumatoid arthritis, hepatitis, organ transplant rejection and psychiatric disorders.
  • Glaxosmithkline Plc (NYSE:GSK): On 06/30/2011, Wells Fargo Co. reported holding 6,725,592 shares with a market value of $288,527,907. This comprised 0.2% of the total portfolio. On 09/30/2011, Wells Fargo Co. reported holding 6,680,200 shares with a market value of $275,825,464. This comprised 0.23% of the total portfolio. The net change in shares for this position over the two quarters is -45,392. About Company: GlaxoSmithKline plc is a research-based pharmaceutical group that develops, manufactures and markets vaccines, prescription and over-the-counter medicines, as well as health-related consumer products. The Group, which also provides laboratory testing and disease management services, specializes in treatments for respiratory, central nervous system, gastro-intestinal and genetic disorders
  • Baxter International Inc. (NYSE:BAX): On 06/30/2011, Wells Fargo Co. reported holding 4,774,194 shares with a market value of $284,971,633. This comprised 0.2% of the total portfolio. On 09/30/2011, Wells Fargo Co. reported holding 4,607,283 shares with a market value of $258,652,865. This comprised 0.21% of the total portfolio. The net change in shares for this position over the two quarters is -166,911. About Company: Baxter International Inc. develops, manufactures, and markets products and technologies related to hemophilia, immune disorders, infectious diseases, kidney disease, trauma and other chronic and acute medical conditions. The Company’s products are used by hospitals, kidney dialysis centers, nursing homes, rehabilitation centers, doctors’ offices, and research laboratories.

(Note: Data regarding Wells Fargo Co.’s stock holdings are sourced from whalewisdom.com. All data are assumed to be accurate.)

Advantage: Check out our interactive stock charts, fundamentals, Twitter stream, and more >>

Improve Your 2011 Financial Health: Join the winning team of stock pickers with Wall St. Cheat Sheet’s acclaimed premium newsletter>>

More from The Cheat Sheet